CAR T cells: Building on the CD19 paradigm.

Area of Science:

• Synthetic immunology
• Immunotherapy
• Cellular engineering

Background:

• Chimeric antigen receptors (CARs) target CD19, revolutionizing treatment for B-cell malignancies.
• CAR T-cells redirect T-cell cytotoxicity independent of MHC expression.
• Remarkable outcomes in relapsed/refractory B-cell malignancies fuel interest in T-cell engineering.

Purpose of the Study:

• Review challenges in extending CAR T-cell therapy to solid tumors and other pathologies.
• Highlight advancements in CAR design, cell manufacturing, and genome editing.
• Explore novel engineered cell types and expanded therapeutic applications.

Main Methods:

• Review of current literature on CAR T-cell therapy.
• Analysis of challenges in solid tumor and non-malignant disease applications.
• Discussion of progress in CAR design and manufacturing technologies.

Main Results:

• CAR T-cell therapy has demonstrated significant success in B-cell malignancies.
• Challenges remain in translating CAR T-cell therapy to solid tumors.
• Advancements in CAR design, manufacturing, and genome editing are improving safety and efficacy.

Conclusions:

• CAR T-cell therapy holds potential beyond B-cell malignancies, including solid tumors, autoimmunity, and infections.
• Ongoing research in engineered cell types and therapeutic strategies promises broader applications.
• Genetically instructed immunity through CAR T-cells is advancing cancer immunotherapy and beyond.